286. Hereditary sideroblastic anemia Clinical trials / Disease details

Clinical trials : 7 / Drugs : 20 - (DrugBank : 10) / Drug target genes : 8 - Drug target pathways : 43

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000023490	2016/08/20	05/08/2016	The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia	The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia - The Safety and Efficacy of 5-Aminolevulinic Acid (ALA) Therapy for Sideroblastic Anemia	Sideroblastic anemia (congenital and acquired)	Food supplement containing 150 mg of ALA phosphate was given per day for 24 weeks. For the evaluation of efficacy and safety, medical examinations as well as urine and blood tests will be performed prior to administration of ALA, then at 2 and 4 weeks, and thereafter every month (up to 12 months).	Department of Hematolgy and Rheumatology, Tohoku University Graduate School of Medicine	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	5	Not applicable	Japan
2	JPRN-UMIN000021407	2016/03/15	15/03/2016	A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia	A study of efficacy and safety of 5-aminolevulinic acid phosphate in patients with sideroblastic anemia - Efficacy and safety of 5-ALA phosphate in patients with sideroblastic anemia	sideroblastic anemia	Orally intake a 150 mg 5-aminolevulinic acid phosphate capsule once a day for up to 24 weeks.	Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University	SBI Pharmaceuticals Co., Ltd	Complete: follow-up continuing	20years-old	80years-old	Male and Female	5	Not applicable	Japan